mTOR inhibitors in cancer therapy.
Cancer Lett
; 319(1): 1-7, 2012 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-22261336
ABSTRACT
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Serina-Treonina Quinasas TOR
/
Neoplasias
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Cancer Lett
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos